scholarly journals Sodium to globulin ratio as a prognostic factor for patients with advanced gastric cancer

2020 ◽  
Vol 11 (24) ◽  
pp. 7320-7328
Author(s):  
Liqun Zhang ◽  
Zhuo Wang ◽  
Jiawen Xiao ◽  
Hao Chen ◽  
Zhiyan Zhang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer

Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e14613-e14613 ◽  
Author(s):  
D. H. Yang ◽  
W. K. Bae ◽  
J. Hwang ◽  
J. Yoon ◽  
I. Chung ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Factor Analysis ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Third Line ◽  
Line Chemotherapy

The vascular endothelial growth factor as a predictive and prognostic factor in patients with advanced gastric cancer treated with docetaxel, cisplatin, and 5-florouracil (DCF) regimen.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15191-e15191
Author(s):  
Sedef H. Aktas ◽  
Hakan Akbulut ◽  
Ozan Yazici ◽  
Nurullah Zengin ◽  
Nalan Akgun ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Cancer Patients ◽  
Predictive Marker ◽  
Vascular Endothelial ◽  
Gastric Cancer Patients ◽  
Endothelial Growth Factor

e15191 Background: Vascular endothelial growth factor (VEGF) is a key element stimulating the angiogenesis in solid tumors. In the current study, we aimed to assess the role of plasma VEGF levels as a prognostic and predictive marker for advanced gastric cancer patients treated with a modified docetaxel, cisplatinum and 5-florouracil (DCF) regimen. Methods: Thirty consecutive patients treated with a modified DCF regimen were included in the study. The plasma VEGF levels of the patients before treatment and following two cycles of chemotherapy were assayed. Results: The modified DCF regimen was well tolerated and yielded a median overall survival (OS) time of 9,0 months and 2-year OS rate of 20%. Good performance status, lower pre-treatment VEGF levels,and decrease in VEGF levels following chemotherapy were found to be independent prognostic factors for OS. Conclusions: The results of the current study suggest that the corrected plasma levels of VEGF could be used as a prognostic factor for advanced gastric cancer patients and a decrease in VEGF levels following 2 cycles of chemotherapy as a predictive marker for patients receiving DCF chemotherapy regimen.

Prognostic factor of nivolumab for advanced gastric cancer patients with poor performance status patients.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. 391-391
Author(s):  
Toshihiko Matsumoto ◽  
Ukyo Okazaki ◽  
Yusuke Kurioka ◽  
Shogo Kimura ◽  
Takao Tsuzuki ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Overall Survival ◽  
Prognostic Factor ◽  
Advanced Gastric Cancer ◽  
Performance Status ◽  
Prognostic Index ◽  
Poor Performance ◽  
Poor Performance Status ◽  
Good Group ◽  
Poor Group

391 Background: Nivolumab has changed the treatment of advanced gastric cancer (AGC). Nivolumab shows better outcome compared to best supportive care in AGC patients who received at least two prior regimen. Although there is not reliable date of poor performance status(PS) AGC patients who received nivolumab. We investigated efficacy and safety of nivolumab for AGC patients with poor PS. Methods: We retrospectively collected clinicopathologic data from patients with AGC who received nivolumab monotherapy in Himeji Red Cross Hospital from October 2017 to June 2019. Results: 49 AGC patients who received nivolumab were analyzed. 27 patients were PS 0 or 1(Good Group), and 22 patients were PS 2 or 3(Poor Group). Median progression free survival and overall survival was 61 days and 180 days in Good Group and 36 days and 85 days in Poor Group. Overall survival (OS) was significantly shorter in Poor group(180 days vs 85 days, p = 0.0255). Disease control rate was 23% in Good group and 9% in Poor group. 33% patients were experienced immune related adverse event (iRAE) in Good Group, and 18% in Poor Group. We investigated prognostic factor of OS in Poor Group such as Royal Marsden Hospital Score(RMH score), modified Glasgow prognostic score(mGPS), and Japan Clinical Oncology Group (JCOG) prognostic index. RMH score and JCOG prognostic index good or moderate group was significantly longer overall survival than poor group (93 days vs 35 days (p = 0.0214)). JCOG prognostic index was most correlated with OS among these tools. Conclusions: This study suggested that nivolumab has a modest effect and is feasible as third line or later line for AGC patients. JCOG prognostic index was suggested to be effective in predicting prognosis in AGC patients who received nivolumab.

Sign in / Sign up

Export Citation Format

Share Document